Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.77 |
| ▸ | GSK3A | P49840 | 2/20 | 0.68 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.68 |
| ▸ | PNP | P00491 | 1/20 | 0.65 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | KRAS | P01116 | 7/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356827 | 0.93 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5347800 | 0.93 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5347821 | 0.93 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5355030 | 0.93 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL2994004 | 0.91 | HINT1 (0.72) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295418 | 0.90 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295421 | 0.90 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5358571 | 0.89 | HINT1 (0.70) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL217117 | 0.89 | HINT1 (0.80) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5367078 | 0.89 | HINT1 (0.67) | HINT1GSK3ARPS6KA3MAPK14PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648910-A2 | ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1543159-A2 | ANTISENSE MODULATION OF ENDOTHELIAL SPECIFIC MOLECULE 1 EXPRESSION | Pharmacia Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005014607-A2 | ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION | ISIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-1203010-A4 | ANTISENSE MODULATION OF FADD EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1200570-A4 | ANTISENSE MODULATION OF P13 KINASE P110 DELTA EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1414842-A2 | ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1206478-A4 | ANTISENSE MODULATION OF MEKK5 EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004021978-A2 | ANTISENSE MODULATION OF ENDOTHELIAL SPECIFIC MOLECULE 1 EXPRESSION | PHARMACIA CORPORATION (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003097662-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003085137-A1 | ANTISENSE MODULATION OF LIVER GLYCOGEN PHOSPHORYLASE EXPRESSION | ISIS PHARMACEUTICALS, INC (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2001005954-A1 | ANTISENSE MODULATION OF LIVER GLYCOGEN PHOSPHORYLASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001000646-A1 | ANTISENSE MODULATION OF JUN N-TERMINAL KINASE KINASE-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000645-A1 | ANTISENSE MODULATION OF INTEGRIN BETA 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000647-A1 | ANTISENSE MODULATION OF ETS-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000873-A1 | ANTISENSE MODULATION OF G-ALPHA-i2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000061786-A2 | ANTISENSE MODULATION OF PDK-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000061599-A1 | ANTISENSE MODULATION OF MICROTUBULE-ASSOCIATED PROTEIN 4 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000061193-A1 | ANTISENSE MODULATION OF MDMX EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000050439-A1 | ANTISENSE MODULATION OF Smad4 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000031103-A1 | ANTISENSE MODULATION OF MEK2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |